Singapore’s precision medicine sector transforming patient care
Singaporean biotechnology firm HistoIndex is scaling its precision medicine technology, specifically its AI-powered Genesis200 imaging system, to improve clinical diagnostics. With support from Enterprise Singapore, the company is expanding its reach to international markets to help doctors assess disease progression and treatment efficacy.
Why it matters
Advancements in non-invasive diagnostic tools can significantly improve patient outcomes and streamline the drug development process for pharmaceutical companies.
With Enterprise Singapore’s support, these home-grown companies are scaling innovations for clinical use and expanding into overseas markets
Dr Gideon Ho (right) co-founded HistoIndex, one of the Singapore companies moving precision medicine from research into clinical care.
In early 2026, a 13-year-old girl and her family faced a worrying possibility: the liver she had received in a transplant as a baby might have deteriorated.
Seeking an additional – and objective – assessment, her specialist turned to Singapore biotechnology company HistoIndex for a clearer answer. Its technology found only minimal scarring, bringing relief to the family.
Behind that reassuring result were years of research to turn complex science into a tool doctors can now use.
HistoIndex’s technology, the result of 16 years of hard work, helps doctors see how a disease is changing and whether a treatment is working. Drug companies can also use the technology to assess potential new medicines.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in